These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 20100660)
41. Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib. Di Fiore A; Pedone C; D'Ambrosio K; Scozzafava A; De Simone G; Supuran CT Bioorg Med Chem Lett; 2006 Jan; 16(2):437-42. PubMed ID: 16290146 [TBL] [Abstract][Full Text] [Related]
42. Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa. Krovat EM; Frühwirth KH; Langer T J Chem Inf Model; 2005; 45(1):146-59. PubMed ID: 15667140 [TBL] [Abstract][Full Text] [Related]
43. Water mediated construction of trisubstituted pyrazoles/isoxazoles library using ketene dithioacetals. Savant MM; Pansuriya AM; Bhuva CV; Kapuriya N; Patel AS; Audichya VB; Pipaliya PV; Naliapara YT J Comb Chem; 2010; 12(1):176-80. PubMed ID: 19950975 [TBL] [Abstract][Full Text] [Related]
44. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors. Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927 [TBL] [Abstract][Full Text] [Related]
45. Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1). Pruitt JR; Pinto DJ; Galemmo RA; Alexander RS; Rossi KA; Wells BL; Drummond S; Bostrom LL; Burdick D; Bruckner R; Chen H; Smallwood A; Wong PC; Wright MR; Bai S; Luettgen JM; Knabb RM; Lam PY; Wexler RR J Med Chem; 2003 Dec; 46(25):5298-315. PubMed ID: 14640539 [TBL] [Abstract][Full Text] [Related]
46. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs. Kleanthous S; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chan C; Clarte MO; Convery MA; Harling JD; Hortense E; Irving WR; Irvine S; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Roethka TJ; Senger S; Shah GP; Stelman GJ; Toomey JR; Watson NS; West RI; Whittaker C; Zhou P; Young RJ Bioorg Med Chem Lett; 2010 Jan; 20(2):618-22. PubMed ID: 20006499 [TBL] [Abstract][Full Text] [Related]
47. Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP). Haffner CD; Diaz CJ; Miller AB; Reid RA; Madauss KP; Hassell A; Hanlon MH; Porter DJ; Becherer JD; Carter LH Bioorg Med Chem Lett; 2008 Aug; 18(15):4360-3. PubMed ID: 18606544 [TBL] [Abstract][Full Text] [Related]
48. Urethanyl-3-amidinophenylalanine derivatives as inhibitors of factor Xa. X-ray crystal structure of a trypsin/inhibitor complex and modeling studies. Sperl S; Bergner A; Stürzebecher J; Magdolen V; Bode W; Moroder L Biol Chem; 2000 Apr; 381(4):321-9. PubMed ID: 10839461 [TBL] [Abstract][Full Text] [Related]
49. Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. Pinto DJ; Orwat MJ; Wang S; Fevig JM; Quan ML; Amparo E; Cacciola J; Rossi KA; Alexander RS; Smallwood AM; Luettgen JM; Liang L; Aungst BJ; Wright MR; Knabb RM; Wong PC; Wexler RR; Lam PY J Med Chem; 2001 Feb; 44(4):566-78. PubMed ID: 11170646 [TBL] [Abstract][Full Text] [Related]
50. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs. Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228 [TBL] [Abstract][Full Text] [Related]
51. Novel factor Xa inhibitors based on a benzoic acid scaffold and incorporating a neutral P1 ligand. Nazaré M; Matter H; Klingler O; Al-Obeidi F; Schreuder H; Zoller G; Czech J; Lorenz M; Dudda A; Peyman A; Nestler HP; Urmann M; Bauer A; Laux V; Wehner V; Will DW Bioorg Med Chem Lett; 2004 Jun; 14(11):2801-5. PubMed ID: 15125936 [TBL] [Abstract][Full Text] [Related]
52. A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin. Katakura S; Nagahara T; Hara T; Iwamoto M Biochem Biophys Res Commun; 1993 Dec; 197(2):965-72. PubMed ID: 8267636 [TBL] [Abstract][Full Text] [Related]
53. Direct Factor Xa and direct thrombin inhibitors: a clinical trial update. Turpie AG Curr Opin Drug Discov Devel; 2009 Jul; 12(4):497-508. PubMed ID: 19562646 [TBL] [Abstract][Full Text] [Related]
54. Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. Ye B; Arnaiz DO; Chou YL; Griedel BD; Karanjawala R; Lee W; Morrissey MM; Sacchi KL; Sakata ST; Shaw KJ; Wu SC; Zhao Z; Adler M; Cheeseman S; Dole WP; Ewing J; Fitch R; Lentz D; Liang A; Light D; Morser J; Post J; Rumennik G; Subramanyam B; Sullivan ME; Vergona R; Walters J; Wang YX; White KA; Whitlow M; Kochanny MJ J Med Chem; 2007 Jun; 50(13):2967-80. PubMed ID: 17536795 [TBL] [Abstract][Full Text] [Related]
55. D-phenylglycinol-derived non-covalent factor Xa inhibitors: effect of non-peptidic S4 linkage elements on affinity and anticoagulant activity. Klimkowski VJ; Watson BM; Wiley MR; Liebeschuetz J; Franciskovich JB; Marimuthu J; Bastian JA; Sall DJ; Smallwood JK; Chirgadze NY; Smith GF; Foster RS; Craft T; Sipes P; Chastain M; Sheehan SM Bioorg Med Chem Lett; 2007 Nov; 17(21):5801-5. PubMed ID: 17881231 [TBL] [Abstract][Full Text] [Related]